Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of “Moderate Buy” from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $8.00.

A number of brokerages have recently commented on MIST. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday. Wells Fargo & Company increased their target price on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday. Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. Finally, HC Wainwright boosted their price target on shares of Milestone Pharmaceuticals from $5.00 to $8.00 and gave the company a “buy” rating in a report on Monday.

Milestone Pharmaceuticals Stock Up 3.4%

Shares of Milestone Pharmaceuticals stock opened at $2.15 on Friday. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $3.06. The business has a fifty day simple moving average of $2.19 and a 200 day simple moving average of $1.93. The stock has a market cap of $183.12 million, a PE ratio of -2.62 and a beta of 0.41.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. Research analysts predict that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Propel Bio Management LLC raised its position in shares of Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after purchasing an additional 3,333,333 shares during the period. Orbimed Advisors LLC bought a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $6,444,000. Simplify Asset Management Inc. increased its stake in Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares in the last quarter. Pathstone Holdings LLC acquired a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $2,000,000. Finally, Boxer Capital Management LLC bought a new position in Milestone Pharmaceuticals in the third quarter valued at approximately $1,333,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.